| This week's sponsor is Premier Research. | |  | It's a New Day for Rare Cancer Research
As innovation and favorable regulation open new treatment options, it's a great time to work in rare cancer research. We know the field well. Download our new white paper to see what's changing, and what it means for you. Premier Research. It's what we do. Best. |
| This week's sponsor is Medpace. | |  | |
Top Stories Monday, October 17, 2016 New evidence has come to light from a series of emails released by the whistle-blowing website WikiLeaks that Hillary Clinton’s legal team worried about FDA commissioner Califf’s ties to the biopharma industry, and wanted someone “willing to stand up to Pharma.” Monday, October 17, 2016 The FDA has denied the New Jersey company’s appeal of a refuse-to-file letter that dates back to February. Monday, October 17, 2016 Merck KGaA has returned a Phase II multiple sclerosis drug to Apitope. The German drugmaker picked up the rights to the peptide-based therapeutic in 2009 and advanced it to the cusp of a Phase IIa readout, but has now decided to relinquish its claim on the drug. Monday, October 17, 2016 Sofinnova has closed its tenth venture fund at $650 million--a big step up from the $500 million the firm raised for its prior fund that dated back to the summer of 2014. Monday, October 17, 2016 After its $7.2 billion buyout of Receptos, Celgene has posted some encouraging midstage data for its acquired asset ozanimod for certain forms of inflammatory bowel disease. Monday, October 17, 2016 Veeva Systems is wading into the fight between Medidata and Oracle for the EDC market. And the cloud software player has poached a pair of VPs from Medidata as part of a hiring spree intended to equip it to take on the incumbents in EDC. Monday, October 17, 2016 Earlier this month, Teva agreed to pick up U.S. and Canadian rights on a pair of biosims from Korea’s Celltrion. But it might not stop with just two. The generics giant may consider purchasing the Korean drugmaker itself. | This week's sponsor is FierceBiotech. | |  | FierceBiotech Presents:
A Half Day Executive Summit
Hosted at the Royal Society of Medicine, London
R&D Challenges: A UK Perspective
Cocktail Reception to follow
27 October, 2016
Register Now! |
| | | Warp Drive Bio has appointed Decibel Therapeutics’ CEO and former Biogen exec Steven Holtzman as its latest board member. Statement Celgene’s latest early-stage data for its Crohn’s pill is “unspectacular but perhaps good enough,” according to TheStreet. Story Analysts at Kalorama Information have posted figures estimating that the embryonic global market for gene editing technologies saw revenues of $382.9 million in 2015. Release Rare blood disorder biotech Ra Pharmaceuticals says it plans to raise $75 million via an IPO by offering 5.8 million shares at a price range of $12 to $14. Story And upstart endocrine biotech Myovant Sciences has also priced its IPO at a meaty $176 million. Story | |
|
Resources Presented by: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Presented by: DocuSign The patients who rely on your scientific leadership are expecting more. Presented by: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. Sponsored By: Salesforce Life sciences companies, like many industries today, face new challenges across the board. Read More. Presented By: ISR Reports Make essential outsourced bioprocessing decisions by staying informed of industry outsourcing practices and contract manufacturer usage patterns with ISR’s Bioprocessing Services and Technologies Market Trends and Outsourcing Dynamics report. Presented By: ISR Reports ISR’s Biosimilars in the US Oncology Market (2nd Edition) report provides data and insights from 101 US-based, board-certified oncologists/hematologist oncologists as to their expectations, fears, and aspirations for biosimilars in oncology. Presented By: ISR Reports Pinpoint the information oncologists find most valuable and the best sales channels for delivering specific types of data/information. Presented by: Covance The role of health economic data has never been more important. Presented by: Covance Leading manufacturers increasingly employ stakeholder research early in development to better identify the needs of patients and providers. Presented By: ISR Reports ISR’s Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021 report provides an overview of the current market dynamics for bioprocessing as well as an outlook on what the marketplace will look like in five years. Presented By: ISR Reports ISR’s CRO Quality Benchmarking – Phase II/III Service Providers (8th Edition) report provides a Consumer Reports-style analysis of Phase II/III CRO service quality from hundreds of users who rated 44 Phase II/III CROs across 26 critical dimensions of quality. Presented by: Patheon Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more! Presented by: Biotech Primer This 3-part webinar series is specifically geared toward the non-science professional who needs to better understand industry terminology, science, techniques and issues. Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance. | 
